$SLS News Article - SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level https://marketwirenews.com/news-releases/sell...80990.html
(0)
(0)
SELLAS Life Sciences Group, Inc. (SLS) Stock Research Links